Efficacy and Safety of Ramucirumab Treatment in Patients with Advanced Colorectal Cancer: A Protocol for Systematic Review and Meta Analysis

Overview

Journal Medicine (Baltimore)

Specialty General Medicine

Date 2020 Jun 17

PMID 32541497

Citations 5

Authors

Man Ju

Honggang Cheng

Kai Qu

Xiangqian Lu

Affiliations

Soon will be listed here.

Abstract

Background: vascular endothelial growth factor receptor 2 (VEGFR-2) has an important role in colorectal cancer pathogenesis and progression. The aim of our study is to provide a protocol for assessing the efficacy and safety of ramucirumab (a monoclonal antibody VEGFR-2 antagonist) for the treatment of advanced colorectal cancer.

Methods: The systematic review will be reported according to the preferred reporting items for systematic reviews and meta-analyses protocols. Relevant randomized controlled trials were searched from PubMed, Cochrane Library, Web of Science, Excerpt Medica Database, China National Knowledge Infrastructure, and Wanfang Database. Papers in English or Chinese published from their inception to February 2020 will be included without any restrictions.Study selection and data extraction will be performed independently by 2 investigators. The clinical outcomes including overall response rate, complete response rate (disease control rate), overall survival, progression-free survival, quality of life, immune function, and adverse events, were systematically evaluated. Review Manager 5.3 and Stata 14.0 were used for data analysis, and a fixed or random-effect model of meta-analysis will be used depending upon the heterogeneity observed between studies. Subgroup analysis will be carried out depending on the availability of sufficient clinical data.

Results And Conclusion: The findings of this systematic review and meta-analysis will be published in a peer-reviewed journal, and provide more evidence-based guidance in clinical practice.

Prospero Registration Number: CRD42020165683.

Citing Articles

Modulation of the Tumor Microenvironment by Microbiota-Derived Short-Chain Fatty Acids: Impact in Colorectal Cancer Therapy.

Gomes S, Rodrigues A, Pazienza V, Preto A Int J Mol Sci. 2023; 24(6).

PMID: 36982144 PMC: 10048801. DOI: 10.3390/ijms24065069.

Classical Angiogenic Signaling Pathways and Novel Anti-Angiogenic Strategies for Colorectal Cancer.

Cao M, Wang Y, Lu G, Qi H, Li P, Dai X Curr Issues Mol Biol. 2022; 44(10):4447-4471.

PMID: 36286020 PMC: 9601273. DOI: 10.3390/cimb44100305.

A post-marketing safety study of ramucirumab with FOLFIRI in patients with metastatic colorectal cancer.

Masuishi T, Nagaoka S, Jin L, Yoshizawa K J Gastrointest Oncol. 2022; 13(4):1701-1710.

PMID: 36092332 PMC: 9459187. DOI: 10.21037/jgo-21-863.

The emerging era of personalized medicine in advanced colorectal cancer.

Wu C, Reid M, Leedham S, Lui R J Gastroenterol Hepatol. 2022; 37(8):1411-1425.

PMID: 35815339 PMC: 7617119. DOI: 10.1111/jgh.15937.

Shunting outcomes in post-hemorrhagic hydrocephalus: A protocol for systematic review and meta-analysis.

Sun T, Guan J, You C, Yang J, Li X, Yuan Y Medicine (Baltimore). 2020; 99(32):e21640.

PMID: 32769930 PMC: 7593010. DOI: 10.1097/MD.0000000000021640.

References

Jackson D, White I, Riley R . Quantifying the impact of between-study heterogeneity in multivariate meta-analyses. Stat Med. 2012; 31(29):3805-20. PMC: 3546377. DOI: 10.1002/sim.5453. View

Lopez A, Harada K, Vasilakopoulou M, Shanbhag N, Ajani J . Targeting Angiogenesis in Colorectal Carcinoma. Drugs. 2019; 79(1):63-74. DOI: 10.1007/s40265-018-1037-9. View

Jiang Y, Fan H, Jiang Y, Song G, Wang F, Li X . Efficacy and safety of FOLFIRI and biotherapy versus FOLFIRI alone for metastatic colorectal cancer patients: A meta-analysis. Medicine (Baltimore). 2018; 96(48):e8767. PMC: 5728752. DOI: 10.1097/MD.0000000000008767. View

Yoon H, Bendell J, Braiteh F, Firdaus I, Philip P, Cohn A . Ramucirumab combined with FOLFOX as front-line therapy for advanced esophageal, gastroesophageal junction, or gastric adenocarcinoma: a randomized, double-blind, multicenter Phase II trial. Ann Oncol. 2020; 30(12):2016. PMC: 8902979. DOI: 10.1093/annonc/mdz454. View

Clarke J, Hurwitz H . Targeted inhibition of VEGF receptor 2: an update on ramucirumab. Expert Opin Biol Ther. 2013; 13(8):1187-96. PMC: 4131847. DOI: 10.1517/14712598.2013.810717. View

Xie Y, Chen Y, Fang J . Comprehensive review of targeted therapy for colorectal cancer. Signal Transduct Target Ther. 2020; 5(1):22. PMC: 7082344. DOI: 10.1038/s41392-020-0116-z. View

Xiao B, Wang W, Zhang D . Risk of bleeding associated with antiangiogenic monoclonal antibodies bevacizumab and ramucirumab: a meta-analysis of 85 randomized controlled trials. Onco Targets Ther. 2018; 11:5059-5074. PMC: 6110629. DOI: 10.2147/OTT.S166151. View

Wang K, Qu X, Wang Y, Dong W, Shen H, Zhang T . The Impact of Ramucirumab on Survival in Patients with Advanced Solid Tumors: A Systematic Review and Meta-Analysis of Randomized II/III Controlled Trials. Clin Drug Investig. 2015; 36(1):27-39. DOI: 10.1007/s40261-015-0355-x. View

Advani S, Kopetz S . Ongoing and future directions in the management of metastatic colorectal cancer: Update on clinical trials. J Surg Oncol. 2019; 119(5):642-652. DOI: 10.1002/jso.25441. View

10.

Bray F, Ferlay J, Soerjomataram I, Siegel R, Torre L, Jemal A . Global cancer statistics 2018: GLOBOCAN estimates of incidence and mortality worldwide for 36 cancers in 185 countries. CA Cancer J Clin. 2018; 68(6):394-424. DOI: 10.3322/caac.21492. View

11.

Cheng H, Sun A, Guo Q, Zhang Y . Efficacy and safety of apatinib combined with chemotherapy for the treatment of advanced gastric cancer in the Chinese population: a systematic review and meta-analysis. Drug Des Devel Ther. 2018; 12:2173-2183. PMC: 6047854. DOI: 10.2147/DDDT.S170678. View

12.

Zeng X, Zhang Y, Kwong J, Zhang C, Li S, Sun F . The methodological quality assessment tools for preclinical and clinical studies, systematic review and meta-analysis, and clinical practice guideline: a systematic review. J Evid Based Med. 2015; 8(1):2-10. DOI: 10.1111/jebm.12141. View

13.

Lee J, Chow N, Wang S, Huang S . Prognostic value of vascular endothelial growth factor expression in colorectal cancer patients. Eur J Cancer. 2000; 36(6):748-53. DOI: 10.1016/s0959-8049(00)00003-4. View

14.

Verdaguer H, Tabernero J, Macarulla T . Ramucirumab in metastatic colorectal cancer: evidence to date and place in therapy. Ther Adv Med Oncol. 2016; 8(3):230-42. PMC: 4872251. DOI: 10.1177/1758834016635888. View

15.

Mody K, Baldeo C, Bekaii-Saab T . Antiangiogenic Therapy in Colorectal Cancer. Cancer J. 2018; 24(4):165-170. DOI: 10.1097/PPO.0000000000000328. View

16.

Shi L, Lin L . The trim-and-fill method for publication bias: practical guidelines and recommendations based on a large database of meta-analyses. Medicine (Baltimore). 2019; 98(23):e15987. PMC: 6571372. DOI: 10.1097/MD.0000000000015987. View

17.

Begg C, Mazumdar M . Operating characteristics of a rank correlation test for publication bias. Biometrics. 1994; 50(4):1088-101. View

18.

Shamseer L, Moher D, Clarke M, Ghersi D, Liberati A, Petticrew M . Preferred reporting items for systematic review and meta-analysis protocols (PRISMA-P) 2015: elaboration and explanation. BMJ. 2015; 350:g7647. DOI: 10.1136/bmj.g7647. View

19.

Geng F, Wang Z, Yin H, Yu J, Cao B . Molecular Targeted Drugs and Treatment of Colorectal Cancer: Recent Progress and Future Perspectives. Cancer Biother Radiopharm. 2017; 32(5):149-160. DOI: 10.1089/cbr.2017.2210. View

20.

Tierney J, Stewart L, Ghersi D, Burdett S, Sydes M . Practical methods for incorporating summary time-to-event data into meta-analysis. Trials. 2007; 8:16. PMC: 1920534. DOI: 10.1186/1745-6215-8-16. View